COUCHE-TARD TAPS ALEX MILLER TO SUCCEED CEO BRIAN HANNASCH

Miller, who's currently chief operating officer, will take over from September 6

RGNX Jul 2024 17.500 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.3500

+0.0400

(+12.90%)

As of 01:45PM EDT. Market open.

Loading interactive chart...

Zacks
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PR Newswire
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
Investor's Business Daily
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.